Anixa Biosciences (CY71) Ratios
3 Followers
Anixa Biosciences Ratios
DE:CY71's free cash flow for Q3 2026 was $-1.77M. For the 2026 fiscal year, DE:CY71's free cash flow was increased by $0.00 and operating cash flow was $-1.77M. See a summary of the company’s cash flow.
| Ratios | Oct 25 | Oct 24 | Oct 23 | Oct 22 | Oct 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.08 | 8.54 | 12.50 | 14.83 | 28.35 |
| Quick Ratio | 8.08 | 8.54 | 12.50 | 14.85 | 28.35 |
| Cash Ratio | 0.63 | 0.51 | 0.45 | 6.07 | 22.94 |
| Solvency Ratio | -5.11 | -4.63 | -4.54 | -6.13 | -8.65 |
| Operating Cash Flow Ratio | -3.65 | -2.93 | -3.06 | -3.19 | -3.89 |
| Short-Term Operating Cash Flow Coverage | -174.95 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 13.76M | $ 18.66M | $ 23.20M | $ 27.99M | $ 34.51M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.06 | 1.08 | 1.05 | 1.05 | 1.02 |
| Debt Service Coverage Ratio | -268.10 | 0.00 | 0.00 | -132.01 | -40625.08 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -133.41 | -40794.07 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net Debt to EBITDA | 0.09 | 0.08 | 0.07 | 0.88 | 2.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 23.33% | 0.00% | 24.80% |
| EBIT Margin | 0.00% | 0.00% | -5243.33% | 0.00% | -2565.63% |
| EBITDA Margin | 0.00% | 0.00% | -5221.43% | 0.00% | -2554.94% |
| Operating Profit Margin | 0.00% | 0.00% | -5243.33% | 0.00% | -2565.56% |
| Pretax Profit Margin | 0.00% | 0.00% | -4728.57% | 0.00% | -2564.05% |
| Net Profit Margin | 0.00% | 0.00% | -4671.90% | 0.00% | -2528.64% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -4728.57% | 0.00% | -2564.05% |
| Net Income Per EBT | 99.08% | 98.87% | 98.80% | 98.72% | 98.62% |
| EBT Per EBIT | 94.25% | 91.81% | 90.18% | 99.25% | 99.94% |
| Return on Assets (ROA) | -67.95% | -58.14% | -38.44% | -44.70% | -35.71% |
| Return on Equity (ROE) | -72.07% | -62.78% | -40.31% | -46.80% | -36.53% |
| Return on Capital Employed (ROCE) | -82.91% | -72.45% | -46.87% | -48.90% | -37.54% |
| Return on Invested Capital (ROIC) | -82.67% | -72.34% | -46.76% | -48.82% | -37.50% |
| Return on Tangible Assets | -67.95% | -58.14% | -38.44% | -44.70% | -35.71% |
| Earnings Yield | -8.15% | -11.24% | -10.02% | -7.99% | -8.90% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.78 | 0.00 | 0.00 |
| Payables Turnover | 0.22 | 0.00 | 0.78 | 0.00 | 2.83 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 1.27 | 0.00 | 2.02 |
| Asset Turnover | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 |
| Cash Conversion Cycle | -1672.92 | 0.00 | 2.27 | 0.00 | -128.94 |
| Days of Sales Outstanding | 0.00 | 0.00 | 469.29 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1672.92 | 0.00 | 467.02 | 0.00 | 128.94 |
| Operating Cycle | 0.00 | 0.00 | 469.29 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.22 | -0.23 | -0.20 | -0.21 | -0.17 |
| Free Cash Flow Per Share | -0.22 | -0.23 | -0.20 | -0.21 | -0.17 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -35.16 | -31.62 | -35.48 | -29.38 | -19.07 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -29.57 | 0.00 | -9.64 |
| Free Cash Flow Yield | -5.35% | -6.57% | -6.34% | -3.82% | -3.39% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -12.15 | -8.89 | -9.98 | -12.51 | -11.24 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 466.18 | 0.00 | 284.11 |
| Price-to-Book (P/B) Ratio | 8.84 | 5.58 | 4.02 | 5.86 | 4.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -18.69 | -15.22 | -15.77 | -26.20 | -29.46 |
| Price-to-Operating Cash Flow Ratio | -18.69 | -15.22 | -15.77 | -26.20 | -29.46 |
| Price-to-Earnings Growth (PEG) Ratio | 0.95 | -0.41 | 0.35 | 0.00 | 5.17 |
| Enterprise Value Multiple | -12.10 | -8.74 | -8.86 | -11.51 | -8.91 |
| Enterprise Value | 133.00M | 110.60M | 97.16M | 157.96M | 116.60M |
| EV to EBITDA | -12.10 | -8.74 | -8.86 | -11.51 | -8.91 |
| EV to Sales | 0.00 | 0.00 | 462.65 | 0.00 | 227.73 |
| EV to Free Cash Flow | -18.54 | -15.08 | -15.65 | -24.33 | -23.61 |
| EV to Operating Cash Flow | -18.54 | -15.08 | -15.65 | -24.33 | -23.61 |
| Tangible Book Value Per Share | 0.43 | 0.59 | 0.75 | 0.93 | 1.22 |
| Shareholders’ Equity Per Share | 0.47 | 0.63 | 0.79 | 0.96 | 1.24 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.01 | 0.00 | 0.02 |
| Net Income Per Share | -0.34 | -0.39 | -0.32 | -0.45 | -0.45 |
| Tax Burden | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
| Interest Burden | 1.00 | 1.00 | 0.90 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 22.71 | 0.00 | 12.09 |
| SG&A to Revenue | 0.00 | 0.00 | 29.96 | 0.00 | 13.82 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 21.06 | 0.00 | 14.65 |
| Income Quality | 0.65 | 0.58 | 0.63 | 0.47 | 0.38 |
Currency in USD
